ArticleMedical sciences (Basel, Switzerland)2025

Durvalumab Is Associated with Prolonged Progression-Free Survival, While Concomitant Chemoradiotherapy May Improve Both Locoregional and Local Control in Elderly Patients with Unresectable NSCLC Stage III: Subanalysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

Franz Zehentmayr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.